Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.
Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.
Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.